Mark Warner, MD
Cardiology · Richmond, VANPI 1679531487
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $807 and has fallen 72.2% since, to $225 in 2025.
Across 148 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$513
- Pfizer$267
- Novartis$237
- Boehringer Ingelheim$199
- Sanofi-aventis U.S. LLC$197
- Boston Scientific$163
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,198100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 5 | $513 |
| Pfizer | 16 | $267 |
| Novartis | 15 | $237 |
| Boehringer Ingelheim | 11 | $199 |
| Sanofi-aventis U.S. LLC | 10 | $197 |
| Boston Scientific | 5 | $163 |
| Esperion Therapeutics, Inc. | 10 | $140 |
| Amgen | 9 | $139 |
| Smith+Nephew | 1 | $136 |
| Imperative Care, Inc | 1 | $129 |
| E.r. Squibb & Sons, L.L.C. | 10 | $124 |
| Philips North America LLC | 6 | $116 |
| Astellas Pharma US Inc | 6 | $112 |
| Regeneron Healthcare Solutions, Inc. | 7 | $103 |
| Johnson & Johnson | 6 | $88 |
| Novo Nordisk | 4 | $75 |
| Abbott | 3 | $66 |
| Lundbeck LLC | 4 | $64 |
| Bayer | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| AstraZeneca | 3 | $42 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 2 | $26 |
| Cardiva Medical, Inc. | 1 | $22 |
| Akcea Therapeutics, Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Atricure, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| Heartflow, Inc. | 1 | $18 |
| Merck | 1 | $14 |
| Medtronic | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$209
- Indigo System$145
- Grafix$136
- SYMPHONY CATHETER$129
- Penumbra System$105
How this compares
Too few cardiology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 402 | $373,271 |
| Repatha SureclickEvolocumab | 80 | $83,170 |
| EntrestoSacubitril/Valsartan | 89 | $81,922 |
| XareltoRivaroxaban | 41 | $38,888 |
| JardianceEmpagliflozin | 26 | $20,551 |
| VascepaIcosapent Ethyl | 12 | $11,212 |
| Praluent PenAlirocumab | 17 | $8,322 |
| Nebivolol Hcl | 91 | $3,789 |
| Metoprolol Succinate | 352 | $3,755 |
| Carvedilol | 318 | $2,430 |
| Atorvastatin Calcium | 240 | $1,930 |
| Amlodipine Besylate | 387 | $1,623 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 70 | $1,593 |
| Losartan Potassium | 173 | $1,297 |
| Bumetanide | 58 | $1,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $267 | $373,271402 claims |
| NovartisEntresto | $237 | $81,92289 claims |
| Johnson & JohnsonXarelto | $88 | $38,88841 claims |
| Boehringer IngelheimJardiance | $199 | $20,55126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other cardiology in Richmond
- John OwensRichmond$4K
- Massimo GiustiRichmond$2K
- Fareeha KhanVienna$66K
- Shakil KhanMidlothian$4K
- Gareth TitusSouth Boston$3K
- Derrick RidleyHampton$2K
- Khosro ShareghiWoodbridge$985
- Rafael AriasFalls Church$514
- M ZaheerArlington$285
- Dean CarpousisArlington$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.